title: Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
abstract: BACKGROUND
  The objective was to evaluate if thrombin-activated fibrinolysis inhibitor (TAFI) polymorphisms (G505A, C1040T, and G-438A), and TAFIa plasma levels are associated with preeclampsia.
  
  
  METHODS
  In a case-control study design, we evaluated preeclampsia patients and women with uncomplicated pregnancies. The TAFI polymorphisms were determined by real-time PCR method, and TAFIa plasma levels were established with a chromogenic assay.
  
  
  RESULTS
  We included 87 women in each group. The TAFIa levels in the preeclampsia group were 20.4 μg/mL (CI 95% 17.3-23.5), while in the control group, they were significantly lower: 13.3 μg/mL (12.0-14.5, p 0.003). There were no differences in the genotype distribution or allelic frequency of TAFI polymorphisms between the two groups. In preeclampsia patients and controls heterozygous for the G505A polymorphism, the TAFIa values were 22.8 (16.7-28.9 μg/mL) and 13.2 (11.3-15.0 μg/mL, p 0.019), respectively. In G505A homozygous polymorphism the TAFIa values were 25.7 (18.7-32.6 μg/mL) and 13.5 (1.6-21.9 μg/mL, p 0.041), respectively. In the C1040T and G-438A TAFI wild type polymorphisms, the TAFIa values were 18.3 (12.5-23.9 μg/mL) and 11.5 (9.9-35.0, p 0.033), and 19.4 (10.9-27.9 μg/mL) and 12.5 (10.8-14.2 μg/mL, p 0.006), respectively, without differences in other genotypes.
  
  
  CONCLUSIONS
  Preeclampsia by itself may be responsible for the increase in TAFIa values rather than the presence of polymorphisms.
authors.affiliation: Posgrado en Ciencias Químicobiológicas, Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, México DF
authors.forename: Maribel
authors.initials: M
authors.lastname: Acosta-Tejeda
authors.forename: Héctor
authors.initials: H
authors.lastname: Baptista-González
authors.forename: Fany
authors.initials: F
authors.lastname: Rosenfeld-Mann
authors.forename: Rocio
authors.initials: R
authors.lastname: Trueba-Gómez
authors.forename: Ethel
authors.initials: E
authors.lastname: García-Latorre
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000235:genetics*; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008800:Mexico; D016017:Odds Ratio; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011225:Pre-Eclampsia / Q000097:blood* / Q000175:diagnosis / Q000235:genetics*; D011247:Pregnancy; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D015415:Biomarkers; D025901:Carboxypeptidase B2